Notice of Special Interest (NOSI): CCRP Administrative Supplement for Collaborative Science to Synergize Chemical Medical Countermeasures Discovery and Early Development
Notice Number:

Key Dates

Release Date:

February 25, 2022

First Available Due Date:
April 03, 2022
Expiration Date:
March 02, 2024

Related Announcements

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

National Eye Institute (NEI)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Neurological Disorders and Stroke (NINDS)


NIAID announces the availability of funds for Administrative Supplements to a subset of existing NIAID-funded/co-funded Chemical Countermeasures Research Program (CCRP) grants and cooperative agreements across the NIH. These funds are intended to stimulate ongoing research by providing CCRP-supported researchers the opportunities to form new collaborations with each other that were not anticipated at the time of submission, review, and funding of the parent award. There must be sufficient progress on the parent project to justify the additional supplemental work. The collaborative activities must be within the scope of the approved aims of the parent award and are expected to generate important new and mutually beneficial opportunities for achieving the goals of the parent project and that of the collaborator’s. Both collaborating parties may submit applications for concurrent consideration provided the proposed efforts are distinct.

Collaborations that bring together ideas, theories, methods, and approaches from different scientific and clinical disciplines are particularly encouraged. Collaborative activities should not include solely the provision of reagents and materials but rather are expected to involve integration and exchange of ideas, knowledge, data, and methodologies that would contribute to success of the parent projects. Collaborations to cross validate models, research tools, or medical countermeasures in the partners’ laboratories are strongly encouraged as are exploratory efforts to establish inter-laboratories biomedical data repositories in compliance with the FAIR (Findable, Accessible, Interoperable, and Reusable digital objects) Data Principles. The data repositories should aim to accept, store, organize, validate, archive, preserve and distribute submission of relevant information from the broader CCRP-supported community. Partnering to access state-of-the-art methodology or data generation and analysis methodologies, such as Artificial Intelligence and Machine Learning (AI/ML), would also fall within the purpose of this collaborative supplement opportunity.

Collaborations must be newly established, that is, there must not be a substantial history of collaboration within the past three years between the grantee Program Director/Principal Investigator (PD/PI) and the collaborator (e.g., there must not be coauthored publications nor any NIH awards that have been funded with the proposed collaborator within the past three years).


  • Only existing CCRP-funded/co-funded awardees funded by these Funding Opportunity Announcements or any reissues of these announcements through the expiration of this Notice, are eligible to apply:

PAR-16-329, PAR-16-330, PAR-16-331, PAR-18-657, PAR-19-039, PAR-19-040, and PAR-20-316

  • Active awards cannot be in the first or last 12 months of the Project Period, exclusive of time in no-cost extension (NCE), at the time of the due date will be considered. Awards in NCE are ineligible to apply.
  • Grantee organizations may submit more than one application, provided that each application is distinct from other administrative supplements or other types of grant applications already funded or under consideration by the NIH.

Description of circumstances for which administrative supplements are available.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

  • PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

  • Application Due Date(s) – 3 April 2022; 1 March 2023; 1 March 2024, by 5:00 PM local time of applicant organization.
  • For funding consideration, applicants must include “NOT-AI-22-029” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
  • Applicants are strongly encouraged to contact the Program Official named in the Notice of Grant Award of the parent CCRP-funded/cofunded grant and the NIAID Program Official to discuss the collaborative project in relation to the parent project prior to submitting an application for this administrative supplement. The pre-submission discussion would facilitate efficient processing of the request.


  • Application budgets are limited to no more than the amount of the current award or $100,000 direct costs (whichever is lower). Funds requested must reflect actual needs of the proposed collaboration in achieving new research objectives that are within scope of the parent projects. Additional salary support for the PD/PI in the supplement application is discouraged.
  • For parent awards with large unobligated balances, an explanation and plans for drawdown must be provided.
  • The project and budget periods are limited to one year and must be within the currently approved project period for the existing parent award.

Research Strategy

  • The Research Strategy section of the application is limited to 6 pages, not including the References Cited. As part of the application, include an abstract of the proposed research that clearly describes the anticipated synergy of the collaboration in developing chemical medical countermeasures. Summarize the scope of the parent and supplemental projects and describe the supplement's specific aims, including research design and methods, data analysis, and planned collaborative activities. Clearly state how the proposed collaboration and supplemental work relates to and enhances achievement of the relevant specific aim(s) and scope of the parent grant. Clinical Trial is not allowed and will be considered nonresponsive to this Notice of Special Interest (NOSI).
  • A formal letter of support (and NIH biographical sketch for any Senior/Key Personnel) must also be provided for all newly proposed collaborative, consultative, and/or contract arrangements.
  • The application must include a letter from the collaborator that briefly describes his/her role, commitment, and unique contributions to the collaboration. The letter must be countersigned by the authorized organizational representative/institutional official of the collaborating institution and included under the Letters of Support section of the application.


Please direct all inquiries to:

Scientific/Research Contact(s)

Dave Yeung, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-796-7237

Financial/Grants Management Contact

Jason A Lundgren
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-2973